Episodes
-
360: NIH grant cuts, FDA transparency questions and biotech M&A
Not summarized yet
-
359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
Not summarized yet
-
358: FDA's gene therapy turmoil, and an alternative model for funding research
Not summarized yet
-
357: The upheaval of CDC's vaccine panel, and drug pricing confusion
Not summarized yet
-
356: An AI experiment at the FDA & Novo trailing in the obesity drug race
Not summarized yet
-
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview
Not summarized yet
-
354: Uncertainty in CRISPR world and the start of more M&A
Not summarized yet
-
353: Trump's drug-pricing plan and a potential Theranos 2.0
Not summarized yet
-
352: A firebrand takes oversight of vaccines, gene therapies
Not summarized yet
-
351: It's gonna be May (in biotech)
Not summarized yet
-
350: Pharma tariffs, and a 'sunshine day' for biotech stocks
Not summarized yet
-
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
Not summarized yet
-
348: Cuts, ousters and drama at the FDA
Not summarized yet
-
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
Not summarized yet
-
346: Zealand's obesity strategy and Immunovant's curious development plan
Not summarized yet
-
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
Not summarized yet
-
344: Trump's FDA commissioner nominee takes the hot seat
Not summarized yet
-
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Not summarized yet
-
342: FDA cuts, zombie biotechs, and too much weight loss?
Not summarized yet
-
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Not summarized yet
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account